Nebenwirkungen · Kisplyx
Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules · Abschnitt 4.8 · PDF-Seite 18
HOS-225033 · Präparat HOS-217386
In the pooled RCC population treated with lenvatinib and everolimus, hypocalcaemia was reported in 4.8% of patients (1.1% were Grade ≥3). In patients where data on individual drug modifications were collected, 0.8% of patients with hypocalcaemia had dose modifications of lenvatinib (0.6% dose interruption and 0.4% dose reduction) and led to permanent treatment discontinuation in no patients. The median time to onset of hypocalcaemia events in lenvatinib plus everolimus-treated patients was 2.9 months.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-26T17:24:00Z · SHA-256 a44a00845e1c56c73ff53a9371d99e0ff78be7df90f4e83eb5595124e9e6b142 · Passage 83065f15991e5d51a52136d78d3fcbde2b2a248bbdbd00772578e58fa91b5e40 · Zeichen 27629–28135 im Abschnitt